Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL I V RTU IN PLASTIC CONTAINER versus METRONIDAZOLE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL I V RTU IN PLASTIC CONTAINER versus METRONIDAZOLE HYDROCHLORIDE.
FLAGYL I.V. RTU IN PLASTIC CONTAINER vs METRONIDAZOLE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
Upon anaerobic reduction of the nitro group, forms toxic intermediates that damage bacterial DNA and inhibit nucleic acid synthesis.
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
Intravenous: 500 mg every 6 hours or 500 mg every 8 hours. Typical adult dose: 500 mg IV every 6 hours.
None Documented
None Documented
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
7-8 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment.
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
Renal 60-80% as unchanged drug and metabolites; fecal 6-15%; biliary minor.
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic